Pro Medicus Posts Record FY26 Half-Year as Cloud Momentum Accelerates.
Pro Medicus (ASX: PME) delivered its strongest half-year result in FY26, driven by major contract wins, expanding cloud deployments, and sustained operating leverage. Revenue increased 28.4% to AU$124.8 million, while underlying EBIT rose 29.7% to AU$90.7 million, maintaining a margin of 72.6%. Profit after tax reached AU$171.2 million. The company remains debt free, holding cash and investments of AU$221.8 million, and declared a higher interim dividend.
During the period, seven new contracts were secured with minimum commitments exceeding AU$280 million, including a AU$170 million, seven-year agreement with University of Colorado Health. Continued acceleration in cloud-based implementations reinforces its transaction-driven SaaS model and strengthens multi-year revenue visibility. With increasing penetration across U.S. academic medical centres, integrated delivery networks, and private healthcare providers, alongside ongoing advancements in AI, cardiology, and digital pathology, Pro Medicus enters the second half of FY26 supported by a robust pipeline and expanding international footprint.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Pro Medicus Posts Record FY26 Half-Year as Cloud Momentum Accelerates.
Pro Medicus (ASX: PME) delivered its strongest half-year result in FY26, driven by major contract wins, expanding cloud deployments, and sustained operating leverage. Revenue increased 28.4% to AU$124.8 million, while underlying EBIT rose 29.7% to AU$90.7 million, maintaining a margin of 72.6%. Profit after tax reached AU$171.2 million. The company remains debt free, holding cash and investments of AU$221.8 million, and declared a higher interim dividend.
During the period, seven new contracts were secured with minimum commitments exceeding AU$280 million, including a AU$170 million, seven-year agreement with University of Colorado Health. Continued acceleration in cloud-based implementations reinforces its transaction-driven SaaS model and strengthens multi-year revenue visibility. With increasing penetration across U.S. academic medical centres, integrated delivery networks, and private healthcare providers, alongside ongoing advancements in AI, cardiology, and digital pathology, Pro Medicus enters the second half of FY26 supported by a robust pipeline and expanding international footprint.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au